Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24133096 | 0.77 | ALDH1A1 (0.42) | ALDH1A1LMNAHSD17B10HPGDALOX15 | |
| SCHEMBL12269675 | 0.77 | TSHR (0.32) | TSHR | |
| SCHEMBL16870267 | 0.76 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10HPGDALOX15 | |
| SCHEMBL731801 | 0.75 | TP53 (0.35) | ALDH1A1GAAKMT2ACYP2C9CYP2C19 | |
| SCHEMBL15649073 | 0.74 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD17B10HPGDALOX15 | |
| SCHEMBL12074232 | 0.74 | SMN1; SMN2 (0.39) | LMNACYP2C19TSHR | |
| SCHEMBL6906507 | 0.73 | ALDH1A1 (0.52) | ALDH1A1LMNAHSD17B10HPGDALOX15 | |
| SCHEMBL725208 | 0.73 | ALDH1A1 (0.52) | ALDH1A1LMNAHSD17B10HPGDALOX15 | |
| SCHEMBL12951628 | 0.72 | — | — | |
| SCHEMBL195331 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779138-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2014-07-15 | — | — | US | disclosed |
| US-8563537-B2 | Camptothecin derivatives as chemoradiosensitizing agents | Sutter West Bay Hospital (US) | 2013-10-22 | — | — | US | disclosed |
| EP-1951231-B1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MED CENTER (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2011-07-28 | — | — | US | disclosed |
| US-7875602-B2 | Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in cancer treatment in combination with radiotherapy; less toxic | SUTTER WEST BAY HOSPITALS (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080318873-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER | 2008-12-25 | — | — | US | disclosed |
| EP-1951231-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | California Pacific Medical Center (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007048002-A2 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | CALIFORNIA PACIFIC MEDICAL CENTER | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093432-A1 | Camptothecin derivatives as chemoradiosensitizing agents | ERCC2, CHEK1, ERCC4 | ALDH1A1 2656/4885LMNA 2280/4885HSD17B10 4630/4885 |
| US-20110184009-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | ERCC2, CHEK1, ERCC4 | ALDH1A1 2656/4885LMNA 2280/4885HSD17B10 4630/4885 |
| US-20080318873-A1 | CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS | ERCC2, CHEK1, ERCC4 | ALDH1A1 2656/4885LMNA 2280/4885HSD17B10 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.